

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Lee et al.  
Serial No.: 09/239,426 Art Unit: 1616  
Filing Date: January 28, 1999 Examiner: S.M. Clardy  
For: LOW VOLATILITY FORMULATIONS OF  
MICROENCAPSULATED CLOMAZONE  
Docket No. 54883 USA-REIS

Assistant Commissioner for Patents  
Washington, DC 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the references, listed on Form PTO-1449 (PTO-2), in accordance with 37 CFR 1.98(a)(2).

The Examiner is respectfully requested to acknowledge receipt of and review these references.

Under 37 CFR 1.97(i), applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office; however, under Reply to Comment 8 of the Federal Register, page 2024, applicants will be informed when information is not considered.

**(1) This Supplemental Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- ☐ before the mailing date of a first Office Action on the merits.
- ☒ after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116


or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:

- ☐ the Statement under 37 CFR 1.97(e) (see "Statement" below);

or

- ☒ the Fee of \$240.00 set forth in 37 CFR 1.17(p); or
- ☐ No fee is owed by the applicants.

- ☐ after the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and



09239426

02/26/2001 SSITHIB1 00000016 061440

180.00 CH

02 FC:126

the Petition Fee set forth in 37 CFR 1.17(i)(1) (see "Statement,"  
"Petition," and "Fees" below).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

*(If this box is checked, do not check any further Statement boxes.)*

**or**

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after make reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

*The person making the statement is:*

- ☐ the inventor(s) who sign(s) below:

\_\_\_\_\_  
*Signature of the Inventor(s)*

\_\_\_\_\_  
*Typed or Printed Name of the Inventor(s)*

**or**

- ☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

\_\_\_\_\_  
*Signature of the Person(s)*

\_\_\_\_\_  
*Typed or Printed Name of the Person*

\_\_\_\_\_  
*Address of Person Signing*

**or**

☒ the undersigned attorney/agent who signs on the basis of the information:

☒ supplied by the inventor(s).

☐ supplied by an individual designated in 37 CFR 1.56(c).

☒ in the attorney's/agent's file.

(3) **Petition**

☐ Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO-1449, in the examination of the above-identified patent application.

(4) **Fees**

☐ No Fee is owed by the applicants.

☒ The IDS Fee of \$240.00 under 37 CFR 1.17(p).

☐ The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(5) **Method of Payment of Fees**

☐ Attached is a check in the amount of \$\_\_\_\_\_.

☒ Charge Account No. **06-1440** in the amount of \$ 240.00.

(6) **Authorization to Charge Additional Fees**

☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. **06-1440**.




(7) **Instructions as to Overpayment**

- ☒ Credit Account No. **06-1440** in the amount of \$ \_\_\_\_\_.
- ☐ Please refund FMC Corporation in the amount of \$ \_\_\_\_\_.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Terence J. Bogle  
Registration No. 44,544  
Tel. No. 609-951-3518


Date: February 19, 2001

**Please address all communication to:**

Patent Administrator  
FMC Corporation  
Intellectual Property Law  
1735 Market Street  
Philadelphia, PA 19103

**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this Supplemental Information Disclosure Statement (along with any document(s) referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date set forth below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Terry Gilson

2/19/2001  
Date